- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT02096653
Fluoroscopically-guided Versus Landmark-guided Sacroiliac Joint Injections
Randomized, Controlled, Double-blind, Comparative-effectiveness Study Comparing Fluoroscopically-guided and Landmark-guided Sacroiliac Joint Injections
In this study, the investigators are attempting to determine whether intra- or extra-articular injections are more effective; the relative prevalence rate of intra-articular and extra-articular SI joint pain; and the accuracy of extra-articular injections using fluoroscopy as the reference standard. 124 consecutive patients with mechanical low back pain below L5, tenderness overlying the SI joint(s) and at least 3 positive provocative maneuvers will be randomized to receive SI joint injections by 2 different approaches.
Group 1 will receive fluoroscopically-guided injections into the joint. Group 2 will receive landmark-guided injections into the tender area around the joint. In order to determine whether the injection in group 2 was intra-articular or extra-articular, an x-ray will be done after the injection to ascertain the location of contrast spread. The primary outcome measure will be pain relief at 1-month. Patients who obtain benefit at 1-month will be followed at 3-months, while those who fail to obtain benefit will exit the study to receive alternative care.
Visão geral do estudo
Status
Condições
Intervenção / Tratamento
Tipo de estudo
Inscrição (Real)
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
California
-
San Diego, California, Estados Unidos
- Naval Hospital-San Diego
-
-
Maryland
-
Baltimore, Maryland, Estados Unidos, 21205
- Johns Hopkins Hospital
-
Rockville, Maryland, Estados Unidos, 20889
- Walter Reed National Military Medical Center
-
-
Pennsylvania
-
Hershey, Pennsylvania, Estados Unidos, 17033
- Penn State
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Age > 18;
- Low back pain principally below the L5 vertebra;
- Three out of 6 positive SI joint provocative maneuvers;
- Agreed to undergo SI joint injection for diagnostic/ therapeutic purposes;
- Average pain score > 3/10 over the past week;
- Pain duration > 6 weeks;
Exclusion Criteria:
- Previous SI joint injection;
- Leg pain > back pain or lower leg pain > upper leg pain
- Active inflammatory spondyloarthropathy (e.g. ankylosing spondylitis);
- Untreated coagulopathy;
- Allergy to contrast dye or bupivacaine;
- Pain > 20 years in duration;
- Poorly controlled psychiatric (e.g. PTSD) or medical (congestive heart failure) condition
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Dobro
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: X-ray guided intra-articular injection
Injection of 40 mg depomethylprednisolone and 2 ml 0.5% bupivacaine into the SI (sacroiliac joint) cavity under fluoroscopic guidance
|
Injection of steroid and local anesthetic into the joint cavity using fluoroscopic guidance
|
|
Comparador Ativo: Landmark-guided SI joint injection
Injection of 40 mg depomethylprednisolone and 2 ml 0.5% bupivacaine at the point of maximal tenderness (3 ml)
|
Injection of steroid into the joint area based on palpation.
The injection may be inside the joint (intra-articular) or outside the joint in the ligaments (extra-articular)
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Average Back Pain at 1 Month Measured Using the Numeric Pain Scale
Prazo: 1 month from the start of treatment
|
This outcome measure compares the average back pain at baseline to the average back pain 1 month after the start of treatment.
This is measured using the Numeric Pain Scale.
The Numeric Pain Scale ranges from 0-10.
0 being no pain at all and 10 being the worst imaginable pain possible.
The group receiving fluoroscopically-guided intra-articular injection is compared to the group receiving landmark-guided injections.
|
1 month from the start of treatment
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Resultados relacionados à incapacidade medidos em 1 mês usando o índice de incapacidade de Oswestry
Prazo: 1 mês após o início do tratamento
|
Capacidade funcional medida pelo índice de incapacidade de Oswestry.
O intervalo de pontuações possíveis para o Índice de Incapacidade de Oswestry é de 0 a 100.
0 é igualado a nenhuma incapacidade e 100 é a incapacidade máxima possível.
|
1 mês após o início do tratamento
|
|
Resultados relacionados à incapacidade medidos em 3 meses usando o índice de incapacidade de Oswestry
Prazo: 3 meses após o início do tratamento
|
Capacidade funcional medida pelo índice de incapacidade de Oswestry.
O intervalo de pontuações possíveis para o Índice de Incapacidade de Oswestry é de 0 a 100.
0 é igualado a nenhuma incapacidade e 100 é a incapacidade máxima possível.
|
3 meses após o início do tratamento
|
|
Worst Back Pain at 1 Month Measured Using the Numeric Pain Scale
Prazo: 1 month from the start of treatment
|
This outcome measure compares the worst back pain at baseline to the worst back pain at 1 months after the start of treatment.
This is measured using the Numeric Pain Scale.
The Numeric Pain Scale ranges from 0-10.
0 being no pain at all and 10 being the worst imaginable pain possible.
The group receiving fluoroscopically-guided intra-articular injection is compared to the group receiving landmark-guided injections.
|
1 month from the start of treatment
|
|
Average Back Pain at 3 Months Measured Using the Numeric Pain Scale
Prazo: 3 months from the start of treatment
|
This outcome measure compares the average back pain at baseline to the average back pain at 3 months after the start of treatment.
This is measured using the Numeric Pain Scale.
The Numeric Pain Scale ranges from 0-10.
0 being no pain at all and 10 being the worst imaginable pain possible.
The group receiving fluoroscopically-guided intra-articular injection is compared to the group receiving landmark-guided injections.
|
3 months from the start of treatment
|
|
Worst Back Pain at 3 Months Measured Using the Numeric Pain Scale
Prazo: 3 months after the start of treatment
|
This outcome measure compares the worst back pain at baseline to the worst back pain at 3 months after the start of treatment.
This is measured using the Numeric Pain Scale.
The Numeric Pain Scale ranges from 0-10.
0 being no pain at all and 10 being the worst imaginable pain possible.
The group receiving fluoroscopically-guided intra-articular injection is compared to the group receiving landmark-guided injections.
|
3 months after the start of treatment
|
|
Patient satisfaction of the procedure at 1 month measured using the Likert Scale
Prazo: 1 month
|
Patient satisfaction is measured at 1 month after the procedure using the Likert Scale.
The range of possible scores for the Likert Scale are 1-5.
I being very unsatisfied and 5 being very satisfied.
|
1 month
|
|
Patient satisfaction of the procedure at 3 months measured using the Likert Scale
Prazo: 3 months
|
Patient satisfaction is measured at 1 month after the procedure using the Likert Scale.
The range of possible scores for the Likert Scale are 1-5.
I being very unsatisfied and 5 being very satisfied.
|
3 months
|
|
Positive categorical outcome
Prazo: 1 month
|
Decrease in average back pain score at 1 month of greater or equal to 2 points coupled with a satisfaction score > 3 on a 1-5 scale
|
1 month
|
|
Positive categorical outcome
Prazo: 3 months
|
Decrease in average back pain score at 3 months of greater or equal to 2 points coupled with a satisfaction score > 3 on a 1-5 scale
|
3 months
|
|
Positive diagnostic blocks
Prazo: 6 hours
|
The percentage of participants who experience greater or equal to 50% pain relief based on their pain diary
|
6 hours
|
Colaboradores e Investigadores
Publicações e links úteis
Publicações Gerais
- Cohen SP, Chen Y, Neufeld NJ. Sacroiliac joint pain: a comprehensive review of epidemiology, diagnosis and treatment. Expert Rev Neurother. 2013 Jan;13(1):99-116. doi: 10.1586/ern.12.148.
- Cohen SP, Bicket MC, Kurihara C, Griffith SR, Fowler IM, Jacobs MB, Liu R, Anderson White M, Verdun AJ, Hari SB, Fisher RL, Pasquina PF, Vorobeychik Y. Fluoroscopically Guided vs Landmark-Guided Sacroiliac Joint Injections: A Randomized Controlled Study. Mayo Clin Proc. 2019 Apr;94(4):628-642. doi: 10.1016/j.mayocp.2018.08.038. Epub 2019 Mar 8.
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Real)
Conclusão do estudo (Real)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Estimativa)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
- NA_00092414
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .